Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission
Tweet
Share
E-mail
FILE PHOTO: The logo of Shionogi & Co Ltd is displayed at their Tokyo branch office in Tokyo, Japan February 24, 2023. REUTERS/Androniki Christodoulou/File Photo
TOKYO (Reuters) - Japan's Shionogi & Co said on Tuesday a global, late-stage study showed its pill-based treatment for COVID-19 was effective in reducing transmission of the disease.
Ensitrelvir, known commercially as Xocova, showed a statistically significant reduction in participants with symptomatic infection after exposure to household contacts with COVID, Shionogi said in a statement.
The Phase 3 SCORPIO-PEP trial involved about 2,400 participants in the United States, South America, Africa, and Asia.
The result follows the drugmaker's May comments that its SCORPIO-HR trial showed the pill failed to reduce common symptoms of the illness, compared to a placebo.
Japan gave the drug full approval in March this year. Although the government bought 2 million courses of the treatment during the pandemic, most of the supply was unused and set to be destroyed, media said.
(Reporting by Rocky Swift; Editing by Clarence Fernandez)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber to cut 3,300 jobs in management overhaul
- Trump pledged fiscal restraint. Instead, debt tops $40 trillion as borrowing costs rise
- Once symbols of war on Islamic State, Kurdish women fighters seek role in new Syria
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
